AVACTA LIFE SCIENCES LIMITED

• ⚠

  Material uncertainty over going concern

  Material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern, as the Company is dependent on its ultimate parent company for further funding and not seeking repayment of amounts currently due, all of which are not guaranteed.

1. AVACTA LIFE SCIENCES LIMITED 2013-03-28 → present
2. APTUSCAN LIMITED 2008-05-29 → 2013-03-28

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern, as the Company is dependent on its ultimate parent company for further funding and not seeking repayment of amounts currently due, all of which are not guaranteed.”

Group structure

1. AVACTA LIFE SCIENCES LIMITED · parent
   1. Affimer Limited 100% · Technologies for bio-therapeutic applications
   2. Avacta Life Sciences Inc. 100% · Technologies for bio-therapeutic applications

Significant events

• “During the year, the Company took the strategic decision to focus its cash resources on growing the Therapeutics Division which the Board believes is now the main value driver of the Company, and has discontinued the Diagnostics-related activities of Avacta Life Sciences Limited.”
• “Expansion arms in indications such as breast cancer, soft tissue sarcoma, and salivary gland cancer were opened to screening in December 2024 and will begin dosing patients early in 2025.”
• “The FDA has granted orphan drug designation to AVA6000 for the treatment of patients with soft tissue sarcoma.”
• “In early 2025, we will select the clinical candidate and advance AVA6103 into IND-enabling studies, with an IND planned to be filed with the FDA Q4 2025 / Q1 2026.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -98.7%

  £3,704,951 → £47,151

• Cash

  -88.1%

  £1,243,543 → £147,871

• Net assets

  -18.2%

  -£106,466,615 → -£125,870,002

• Employees

  -29.4%

  51 → 36

• Operating profit

  -13.9%

  -£19,143,670 → -£21,811,139

• Profit before tax

  -12.3%

  -£19,400,139 → -£21,777,627

• Wages

  -20.5%

  £3,684,927 → £2,928,514

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers